business
French biotech stock soars 31% after new data on experimental medicine
Key takeaways
- Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
- The move comes after it crashed around 44% on June 2, following a data set that showed there were cancer cases among patients taking the highest dose of its experimental medicine obefazimod for ulcerative colitis (UC).
- Additional data on the late-stage clinical trial, released late on Monday, showed that malignancies were in line with levels normally seen in UC patients.
Livestream Menu Make Itselect USAINTLLivestream Search quotes, news & videos Livestream Watchlist SIGN INCreate free account Markets Business Investing Tech Politics Video Watchlist Investing Club PROLivestream Menu
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease, clawing back heavy losses from earlier in the month when the same trial had investors questioning the drug's future.
Abivax stock was last trading up 29.9%. The move comes after it crashed around 44% on June 2, following a data set that showed there were cancer cases among patients taking the highest dose of its experimental medicine obefazimod for ulcerative colitis (UC).
Article preview — originally published by CNBC. Full story at the source.
Read full story on CNBC →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from CNBC alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop